Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses trial results showing the safety and efficacy of zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.
Holistic wellness and helping patients manage the toxins in their outside life are just a few of the focuses at Wobbly Arrow Wellness.
Ronald T. Piervincenzi, PhD, CEO of US Pharmacopeia, discusses the challenges that lie ahead as we move into the third year of the COVID-19 pandemic, as well as other major developments on the horizon for pharmacists in 2022.
Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the primary endpoint in the trial assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone in the treatment of patients with newly diagnosed multiple myeloma.
Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses the adverse events experienced by patients with previously untreated chronic lymphocytic leukemia when treated with zanubrutinib, obinutuzumab, and venetoclax.
Ronald T. Piervincenzi, PhD, CEO of US Pharmacopeia, discusses what stands out as the biggest challenge from the past year and what role USP and pharmacists had in overcoming that challenge.
Luciano Costa, MD, PhD, associate director for clinical research at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, on the safety and efficacy of Dara-KRd in the treatment of patients with newly diagnosed multiple myeloma.
Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, addresses the primary endpoint in the trial assessing zanubrutinib, obinutuzumab, and venetoclax in previously untreated chronic lymphocytic leukemia.
Sarah Temkin, MD, associate director for clinical research in the Office of Research on Women’s Health (ORWH) at the National Institutes of Health (NIH), discusses how the work of the NIH ORWH impacts pharmacy practice.
The panel considers optimal therapy for recurrent CDI, particularly the role of fecal microbiota transplantation.
Centering their discussion around a patient case of CDI, experts discuss optimal therapy selection given available agents and guidelines.
Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses minimum residual disease-driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax in previously untreated chronic lymphocytic leukemia.
Laura Lee Hall, PhD, president of the Center for Sustainable Health Care Quality and Equity, addresses disparities occurring in diabetes care among racial and ethnic populations.
Sarah Temkin, MD, associate director for clinical research in the Office of Research on Women’s Health (ORWH) at the National Institutes of Health (NIH), discusses the scope and focus of the work of NIH ORWH.
Bradley J. Monk, MD, FACS, FACOG, leads the discussion on approaching treatment selection of PARP inhibitors for the treatment of ovarian cancer.
Sarah Hayward, PharmD, BCOP, and Bradley J. Monk, MD, FACS, FACOG, compare the safety and efficacy among PARP inhibitors—niraparib, olaparib, and rucaparib—for ovarian cancer treatment.
Sarah Hayward, PharmD, BCOP; Jennifer MacDonald, PharmD, BCOP; and Bradley J. Monk, MD, FACS, FACOG, discuss the relevance of PARP inhibition in the treatment of ovarian cancer and comment on the use of biomarker testing for treatment initiation.
A panel of experts discuss the future of psychedelic medicine and the role of the pharmacy in that future.
Cutaquig was recently approved for the treatment of pediatric patients aged 2 years and older with primary humoral immunodeficiency.
An overview of the types of biomarkers that play a role in the manifestation of Waldenstrom macroglobulinemia.
The characteristics of Waldenstrom macroglobulinemia that distinguish the disease from other types of lymphomas.
Data from a couple of new molecules could be encouraging for the treatment of acute myeloid leukemia and diffuse large B-cell lymphoma
In addition to data showing the durable efficacy of acalabrutinib, other data presented at ASH 2021 demonstrate that the new tablet formulation of the drug supports ease of use for patients
Most adverse effects are very tolerable and easily managed, including headaches, diarrhea, and some neutropenias or infections
Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses the results of a longer-term follow up for iFCR therapy for individuals with chronic lymphocytic leukemia .
Acalabrutinib could offer a high level of confidence for patients looking at a long course of disease.
Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how common chronic lymphocytic leukemia is for younger individuals
Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how the results of a longer term study differ for individuals who were younger with chronic lymphocytic leukemia as opposed to those who are older.
Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, discusses ongoing trials assessing efficacy and safety of asciminib in the treatment of chronic myeloid leukemia.
Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses what the results of the initial iFCR study showed and what the highlights of the longer-term follow up were for individuals with chronic lymphocytic leukemia.
